Bumpus Namandje 4

What Happened
Bumpus Namandje, a director of Recursion Pharmaceuticals (RXRX), sold 4,386 shares on June 3, 2026, at $3.54 per share, for a total proceeds of $15,526. The transaction was a sale (code S) and not a purchase or option exercise.

Key Details

• Transaction date: 2026-06-03; Filing date: 2026-06-04 (appears timely).
• Price and size: 4,386 shares at $3.54 each; total value reported $15,526.
• Shares owned after transaction: Not specified in the provided filing excerpt.
• Footnote: The sale was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 3, 2026.
• Transaction type: Open-market sale (routine disposition under a pre-set plan).

Context
A 10b5-1 plan indicates the trades were pre-scheduled under an established trading plan and may be routine rather than reflecting a contemporaneous view of the company. Sales are common for liquidity or portfolio reasons and, by themselves, are generally less informative than insider purchases.